- The inhalable vaccine, which can be administered more easily than intramuscular injections, will be administered by nebulizer.
- There are no publicly available verified or peer-reviewed data on the effectiveness of the new vaccine.
- China has so far approved eight other locally-made injectable vaccines since 2020.
BEIJING (Reuters) – Chinese drug regulators approved the world’s first inhalable COVID-19 vaccine, made by Tianjin-based manufacturer CanSino Biologics, boosting the company’s share price 7% on Monday.
The National Medical Products Administration has cleared the vaccine for emergency use as a booster, the company said in a statement to the Hong Kong Stock Exchange on Sunday.
Following the announcement, the company’s shares jumped 14% on Monday morning before closing 7.1% higher than their opening value.
The needle-free vaccine – which can be stored and administered more easily than intramuscular injections – will be administered via a nebulizer, the company said.
“The approval will have a positive impact on company performance if the vaccine is subsequently purchased and used by relevant government agencies,” the statement added.
The company did not provide details on when the adenoviral vector vaccine will be made available to the public.
There are no publicly available verified or peer-reviewed data on the effectiveness of the new vaccine.
Scientists from several countries, including Cuba, Canada and the United States, are also testing inhalable vaccines against COVID-19.
China has so far approved eight other locally-made injectable vaccines since 2020.
But the country’s drug administrator has yet to greenlight foreign vaccines, including mRNA injections produced by Pfizer/BioNTech or Moderna that have better efficacy rates compared to others. types of vaccines.
China is the only major economy to stick to a zero COVID policy, disrupting travel and business.
Authorities across the country are now under pressure to curb local virus outbreaks ahead of a key policy meeting next month.
The southern tech hub of Shenzhen, with more than 18 million people, imposed a weekend lockdown in most parts of the city on Saturday, while more than 21 million people in the southwestern metropolis from Chengdu undergo mass testing from Monday to Wednesday.
China has administered more than 3.4 billion COVID vaccines, the National Health Commission said Monday without providing details on the percentage of the population vaccinated.